欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是 分享到:

中国临床药理学与治疗学 ›› 2019, Vol. 24 ›› Issue (8): 933-937.doi: 10.12092/j.issn.1009-2501.2019.08.014

• 药物治疗学 • 上一篇    下一篇

促红细胞生成素对急性脊髓损伤患者血清降钙素基因相关肽的影响

刘亚东1,卢小伟2,刘志刚3   

  1. 1湖北省十堰市国药东风总医院骨外科,2心功能室,十堰 442008,湖北; 3武汉市第三医院骨科,武汉 430074,湖北
  • 收稿日期:2019-01-09 修回日期:2019-07-08 出版日期:2019-08-26 发布日期:2019-08-30
  • 通讯作者: 卢小伟,女,本科,主治医师,研究方向:心电图。 Tel:13733593963 E-mail:luxiaowei855@163.com
  • 作者简介:刘亚东,男,本科,副主任医师,研究方向:骨外科。 Tel:13872832015 E-mail:liuyadong62@163.com
  • 基金资助:

    2014年十堰市科学技术研究与开发项目(14Y50)

Effects of EPO on serum calcitonin gene-related peptide in patients with acute spinal cord injury

LIU Yadong 1, LU Xiaowei 2, LIU Zhigang 3   

  1. 1 Department of Bone Surgery, Sinopharm Dongfeng General Hospital, Shiyan 442008, Hubei, China; 2 Heart Function Examination Room, Sinopharm Dongfeng General Hospital, Shiyan 442008, Hubei, China; 3 Department of Orthopedics, the Third Hospital of Wuhan, Wuhan 430074, Hubei, China
  • Received:2019-01-09 Revised:2019-07-08 Online:2019-08-26 Published:2019-08-30

摘要:

目的:探讨促红细胞生成素(erythropoietin,EPO)对急性脊髓损伤患者血清降钙素基因相关肽(calcitonin gene-related peptide,CGRP)的影响。方法:2013年9月到2018年2月选择在本院进行急诊的急性脊髓损伤患者156例,根据治疗方法的不同分为EPO组80例与对照组76例,对照组给予甲强龙冲击治疗,EPO组给予甲强龙联合EPO治疗,两组都连续治疗4周。结果:治疗后两组患者的脊髓神经功能评分都显著高于治疗前(P<0.05),EPO组也显著高于对照组(P<0.05)。EPO组治疗后的红细胞与血红蛋白值显著高于治疗前(P<0.05),也高于对照组(P<0.05),对照组治疗前后红细胞与血红蛋白值对比差异无统计学意义(P>0.05)。EPO组治疗期间的消化道出血、感染、肝肾功能异常等并发症发生率为8.8%,对照组为9.2%(P>0.05)。治疗后两组的血清CGRP值都显著高于治疗前,EPO组也显著高于对照组(P<0.05)。结论:EPO在急性脊髓损伤患者中的应用具有很好的安全性,有利于血清CGPR的释放,改善机体营养状态,提高患者的脊髓神经功能。

关键词: 促红细胞生成素, 急性脊髓损伤, 降钙素基因相关肽, 甲强龙

Abstract:

AIM: To investigate the effects of erythropoietin (EPO) on serum calcitonin gene-related peptide (CGRP) in patients with acute spinal cord injury. METHODS: From September 2013 to February 2018, 156 cases of patients with acute spinal cord injury who were selected for emergency department in our hospital were divided into 80 cases of EPO group and 76 cases of control group according to different treatment methods. The control group was given the treatment of methylprednisolone. The EPO group was given EPO treatment based on the treatment of the control group, and both groups were treated continuously for 4 weeks.RESULTS:The spinal nerve function scores of the two groups were significantly higher than those before treatment (P<0.05), and the EPO group were also significantly higher than the control group (P<0.05). The red blood cell and hemoglobin values in the EPO group were significantly higher than those before treatment (P<0.05), and were also higher than the control group (P<0.05). There was no significant difference in the red blood cell and hemoglobin values before and after treatment in the control group (P>0.05). The incidence of gastrointestinal bleeding, infection, liver and kidney dysfunction during the treatment of EPO group were 8.8%, and that of the control group were 9.2%, there was no significant difference compared between the two groups (P>0.05). The serum CGRP values of the two groups were significantly higher than those before treatment, and the EPO group was also significantly higher than the control group (P<0.05). CONCLUSION:EPO is safe for patients with acute spinal cord injury; it can promote the release of serum CGPR, improves the nutritional status of the body and the spinal nerve function of patients.

Key words: erythropoietin, acute spinal cord injury, calcitonin gene-related peptide, methylprednisolone

中图分类号: